FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 567 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR Rediscovered Drugs Hit Leukemia from Two Different Angles July 21, 2020 Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing... May 18, 2022 Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient... May 11, 2022 Foodie Fridays-Gazpacho: A Favorite Summer Soup August 6, 2021 Load more HOT NEWS Foster Teen With A Passion For Painting Is Patiently Waiting For... EMA Recommends Extension of Therapeutic Indications for Tislelizumab What to Know When Searching for Cancer Information Online: An Expert... Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate...
